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Plasmacytoid dendritic cells appear 
inactive during sub-microscopic 
Plasmodium falciparum blood-stage 
infection, yet retain their ability to 
respond to TLR stimulation
Jessica R. Loughland1, Gabriela Minigo1, Derek S. Sarovich1,2, Matt Field3, Peta E. Tipping1,9, 
Marcela Montes de Oca4, Kim A. Piera1, Fiona H. Amante4, Bridget E. Barber1,5, Matthew J. 
Grigg1,5, Timothy William5,6, Michael F. Good7, Denise L. Doolan3,4, Christian R. Engwerda4, 
Nicholas M. Anstey1,8, James S. McCarthy4 & Tonia Woodberry1
Plasmacytoid dendritic cells (pDC) are activators of innate and adaptive immune responses that express 
HLA-DR, toll-like receptor (TLR) 7, TLR9 and produce type I interferons. The role of human pDC in 
malaria remains poorly characterised. pDC activation and cytokine production were assessed in 59 
malaria-naive volunteers during experimental infection with 150 or 1,800 P. falciparum-parasitized red 
blood cells. Using RNA sequencing, longitudinal changes in pDC gene expression were examined in five 
adults before and at peak-infection. pDC responsiveness to TLR7 and TLR9 stimulation was assessed 
in-vitro. Circulating pDC remained transcriptionally stable with gene expression altered for 8 genes 
(FDR < 0.07). There was no upregulation of co-stimulatory molecules CD86, CD80, CD40, and reduced 
surface expression of HLA-DR and CD123 (IL-3R-α). pDC loss from the circulation was associated with 
active caspase-3, suggesting pDC apoptosis during primary infection. pDC remained responsive to TLR 
stimulation, producing IFN-α and upregulating HLA-DR, CD86, CD123 at peak-infection. In clinical 
malaria, pDC retained HLA-DR but reduced CD123 expression compared to convalescence. These 
data demonstrate pDC retain function during a first blood-stage P. falciparum exposure despite sub-
microscopic parasitaemia downregulating HLA-DR. The lack of evident pDC activation in both early 
infection and malaria suggests little response of circulating pDC to infection.
Innate recognition of Plasmodium parasites is critical for the induction of appropriate anti-malarial immune 
responses1. Plasmacytoid dendritic cells (pDC) are important mediators of both innate and adaptive immune 
responses (reviewed in ref. 2). Human pDC are HLA-DR+ blood cells that lack the lineage-associated markers 
CD3, CD19, CD14, CD56, CD11c and express high levels of the IL-3 receptor alpha chain CD123. Unlike mye-
loid DC, pDC express toll-like receptor (TLR) 7 and TLR9 thereby allowing recognition of single-stranded RNA3 
and DNA4, 5, respectively. Upon recognition of pathogen nucleic acids, pDC produce large amounts of immune 
regulatory type I interferons (IFNs). pDC MHC class I and II molecules allow pDC antigen-presentation to CD8+ 
T cells (cross-presentation)6 and CD4+ T cells7. In addition, pDC regulate the generation of plasma cells and 
antibody responses8, 9.
1Menzies School of Health Research, Darwin, Australia and Charles Darwin University, Darwin, Australia. 2Centre for 
Animal Health Innovation, Faculty of Science, Health, Education and Engineering, University of the Sunshine Coast, 
Sippy Downs, Queensland, Australia. 3Australian Institute of Tropical Health and Medicine, James Cook University, 
Cairns, Australia. 4QIMR Berghofer Medical Research Institute, Brisbane, Australia. 5Infectious Diseases Unit, 
Queen Elizabeth Hospital, Kota Kinabalu, Sabah, Malaysia. 6Sabah Department of Health, Kota Kinabalu, Sabah, 
Malaysia. 7Griffith University, Gold Coast, Australia. 8Royal Darwin Hospital, Darwin, Australia. 9Present address: 
Royal Darwin Hospital, Darwin, Australia. James S. McCarthy and Tonia Woodberry contributed equally to this work. 
Correspondence and requests for materials should be addressed to J.R.L. (email: jessica.loughland@menzies.edu.au)
Received: 24 January 2017
Accepted: 5 April 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific RepoRts | 7: 2596  | DOI:10.1038/s41598-017-02096-2
The role of pDC in Plasmodium infection remains unclear. Plasmodium parasite protein-DNA com-
plexes are thought to activate TLR910, 11, and Plasmodium-derived RNA can trigger type I IFN responses in a 
TLR7-dependent12 and -independent fashion13 in mice. The Plasmodium agonist of human TLR7 remains to be 
identified.
Murine models of malaria show differing pDC responses, depending on the mouse strain and parasite species. 
Across mouse strains, pDC upregulate CD8612, 14, 15, MHC class II14 or CD4012 following Plasmodium infection. 
Production of type I IFN by pDC has been demonstrated at the transcriptional14, 16 and protein level15, 17 following 
infection with three rodent-infecting Plasmodium species. The relevance of pDC activation in murine malaria 
is debated. In the P. chabaudi model of chronic infection and the P. berghei model of cerebral malaria, pDC are 
considered not relevant for the control of blood parasitaemia or disease outcome despite their activation12, 14, 16. 
Most recently, pDC derived type I IFN early during infection has been reported as essential for the induction 
of protective immune responses against lethal P. yoelii YM17, and Plasmodium parasites may prevent early pDC 
type-I IFN release by activating cross-regulatory type-I IFN pathways17.
Much less is known about the role of pDC in human malaria, mainly due to limitations intrinsic to human 
studies and restrictions to peripheral blood. There is a consensus that blood pDC numbers decline in acute clin-
ical malaria18–22. However, it is unclear whether pDC loss is due to migration18 or cell death19. Evaluation of pDC 
maturation in malaria has been limited to the assessment of surface CD86 and HLA-DR. CD86 upregulation 
has been reported in children with severe malaria15, P. falciparum infected pregnant women20 and some patients 
with acute vivax malaria23, whilst HLA-DR is not upregulated in severe malaria15, 24. In agreement with this, a 
Malian study of two ethnic groups with differing susceptibility to symptomatic malaria shows in P. falciparum 
infected malaria-susceptible Dogon, pDC downregulate HLA-DR expression, lack upregulation of CD86 and 
show impaired responsiveness to TLR9 stimulation. Circulating pDC in P. falciparum infected Fulani, an ethnic 
group less susceptible to symptomatic malaria, on the contrary, display a mature phenotype with upregulated 
CD86 and HLA-DR expression and strong TLR9 responsiveness25. These studies, together with recent murine 
studies15, 17, suggest that pDC may play an integral part in the acquisition of clinical immunity.
Surprisingly, our recent report on early P. falciparum blood-stage infection found pDC to be minor contrib-
utors to the early IFN-α response26. We have also shown, circulating pDC decline early during the pre-patent 
phase of a primary infection27. These findings, together with the recent report of inhibited type I IFN release 
from pDC during early P. yoelii infection17 and our past identification of profoundly impaired CD1c+ myeloid 
DC in very early P. falciparum infection28, prompted us to investigate pDC activation and function in more detail. 
Controlled human malaria infection (CHMI), provides the unique ability to assess host responses during P. fal-
ciparum blood-stage infection with each individual’s baseline response before infection. To characterise pDC 
activation and function in a primary P. falciparum blood-stage infection, we isolated highly purified pDC for gene 
expression analysis, monitored the expression of co-stimulatory markers CD86, CD80 and CD40 and measured 
pDC responsiveness to TLR7 and TLR9 stimulation at baseline and at peak-infection.
Results
Circulating pDC gene expression is predominantly stable after primary pre-patent P. falci-
parum CHMI. We isolated blood pDC at >98% purity from five volunteers at baseline and at peak parasitae-
mia following intravenous infection with 1,800 pRBC (n = 5, median parasitaemia 4,754/mL [1,320–11,929]). 
Transcriptional gene expression changes were investigated by RNA sequencing as described in the methods. 
Globally, there were only modest changes (false detection rate, FDR < 0.07) in pDC gene expression. Eight gene 
transcripts had significantly decreased or increased gene expression (FDR < 0.07, Supplementary Figure 1), when 
baseline was compared to peak-infection. A summary of the top 10 genes that increased and top ten genes that 
decreased expression at peak-infection is presented in Table 1. No P. falciparum RNA signal was detected (data 
not shown).
Circulating pDC of immature phenotype during early P. falciparum CHMI. To phenotypically 
characterise pDC during early P. falciparum infection we assessed maturation markers; CD86, CD40, CD80, 
HLA-A,B,C, HLA-DR and CD123 (IL-3Rα) expression on pDC before and at peak-infection for participants 
infected with either 150 pRBC or 1,800 pRBC. Mean parasitaemia was determined by PCR29. Participants admin-
istered 150 pRBCs reached peak parasitaemia on day 10 (n = 1, parasitaemia 12,750/mL), or day 11 (n = 11, 
median parasitaemia 2,380/mL [IQR 696–5085]), whereas participants administered 1,800 pRBCs reached peak 
parasitaemia on day 7 (n = 23, median parasitaemia 6,877/mL [IQR 4,759–12,813]) or day 8 (n = 24, median 
parasitaemia 4,970/mL [IQR 666–18,065]) (Fig. 1A). Circulating pDC were identified in whole blood as lineage 
marker negative (CD3, CD14, CD19, CD20, CD34 and CD56), HLA-DR+, CD11c− and CD123+ (Fig. 1B). In 
fresh whole blood, less than 1% of pDC expressed CD86, CD40 or CD80 before infection or at peak parasitaemia 
(Fig. 1C). pDC expression of CD123, the alpha subunit to the IL-3 receptor (IL-3Rα)30, frequently used to iden-
tify pDC subsets31, significantly reduced at peak parasitaemia and failed to recover by 24 hours after antimalarial 
treatment (Fig. 1D,E). HLA-DR expression on pDC also reduced in both cohorts at peak parasitaemia (Fig. 1D,E). 
Additionally, HLA-A,B,C expression increased on pDC in the 1,800 pRBC cohort, although the increase was not 
statistically significant (Fig. 1E). In accordance with previous reports32, 33, pDC did not uptake FITC-dextran 
particulate antigen at baseline and this did not change with infection (data not shown). In clinical malaria, circu-
lating pDC showed a similarly immature phenotype lacking upregulation of CD86 or HLA-DR and significantly 
reduced CD123 expression during acute disease compared to convalescence (Fig. 2).
Reduced circulating pDC number is associated with increased active caspase-3 expres-
sion. Circulating pDC numbers were determined longitudinally in both the 1,800 pRBC and 150 pRBC 
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infection cohorts. pDC significantly declined at peak parasitaemia and continued to fall 24 hours after antima-
larial drug treatment in the 1,800 pRBC infection cohort (Fig. 3A, grey bars). In the lower 150 pRBC cohort, 
pDC number fell significantly 24 hours pre and post peak parasitaemia (Fig. 3A, white bars). After antimalarial 
drug treatment, pDC numbers remained low at 48 and 72 hours (Fig. 3A). To determine if the loss of pDC was 
attributable to an increase in pDC apoptosis, circulating pDC were examined for the presence of the active form 
of caspase-3, a hallmark apoptosis marker. Caspase-3 is an executioner caspase, essential to both intrinsic and 
extrinsic apoptotic pathways34. There was no evidence of active caspase-3 in blood pDC following infection with 
150 pRBC (n = 6; median 1% [IQR 1–3%] caspase-3, Fig. 3B). In contrast, following 1,800 pRBC infection, we 
observed significantly increased active caspase-3 in pDC (n = 30; median 6.5% [IQR 2–18] caspase-3, Fig. 3B). 
Longitudinal changes in circulating pDC number and active caspase-3 expression were assessed in the 1,800 
pRBC cohort, 48 hours before peak parasitaemia (day 6) to 48 hours after antimalarial treatment (day 10). As 
P. falciparum infection progressed, the number of circulating pDC declined, while pDC expressing caspase-3 
increased (Fig. 1C). Thus, we show for the first time that pDC are apoptotic during the higher dose P. falciparum 
infection.
Circulating pDC retain the ability to produce IFN-α and TNF during controlled P. falciparum 
infection. To assess pDC function during early P. falciparum infection we evaluated IFN-α, TNF, IL-10 and 
IL-12 cytokine production and maturation in response to TLR stimulation (n = 8, Fig. 4A). pDC were identified 
as lineage−, HLA-DR+, CD11c− and CD123 (IL-3Rα)+ (Fig. 4A). At peak-infection, more pDC produced IFN-α 
in response to TLR7 (p = 0.02, Fig. 4B) or TLR9 stimulation (p = 0.08, Fig. 4C), when compared to baseline 
hence, the ability of pDC to produce IFN-α was not diminished during early P. falciparum blood-stage infection. 
IFN-α producing pDC always co-produced TNF (Fig. 4A) and infection did not change the proportion of pDC 
producing TNF alone (Fig. 4B,C). A comparison between cytokine MFI at peak parasitaemia and baseline (day 
0) showed that TLR9-stimulated pDC expressed more IFN-α at peak-infection (Fig. 4D), whilst TNF production 
remained unchanged (Fig. 4E). No IL-10 or IL-12 production by pDC was detected. The same pattern of cytokine 
response (dual IFN-α/TNF and no IL-12 or IL-10) was observed when PBMC or fresh whole blood was used in 
the assay.
Circulating pDC significantly increased HLA-DR and CD123 surface expression upon TLR7 or TLR9 stim-
ulation, at both baseline and peak parasitaemia (n = 8, Fig. 5A,B). CD86 expression increased significantly fol-
lowing TLR7 stimulation at both baseline and peak parasitaemia, but not upon TLR9 stimulation with CpGA 
(Fig. 5C), as previously reported35. There was no significant change in pDC HLA-DR, CD86 or CD123 expres-
sion, either without stimulation (NIL) or following TLR7 or TLR9 stimulation, when baseline was compared to 
peak-infection in eight individuals.
Discussion
Here, we have shown pDC are not activated and remain functional during early P. falciparum infection. To the 
best of our knowledge, this is the first study to sequence RNA from highly purified pDC and compare gene 
FDR P-value
Genes Upregulated
NLRC5 0.02 0.000005
C14orf119 0.03 0.00001
TSG101 0.04 0.00003
GPATCH11 0.10 0.0001
NMI 0.19 0.0004
HLA-F 0.19 0.0004
ENP22 0.19 0.0004
KCNA5 0.25 0.0006
ENSG021574 0.28 0.0008
SAC3D1 0.37 0.002
Genes Downregulated
DMBT1 1.05E−15 9.8 × 1020
AREGB 0.03 0.00001
RNF139 0.02 0.000005
CRYM 0.03 0.00001
BAG3 0.067 0.00006
ENSG0253333 0.09 0.00008
ENSG0257513 0.19 0.0004
CXCR4 0.11 0.0002
AREG 0.23 0.0005
KRTCAP3 0.33 0.001
Table 1. pDC gene expression summary. Genes in bold have a False Detection Rate (FDR) < 0.07.
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expression before and at the peak of a primary P. falciparum CHMI. Unexpectedly, we found pDC gene expres-
sion to be largely stable in early sub-microscope infection. The observed minimal change in gene expression, 
together with an absence of activation/maturation phenotype by flow cytometry suggests, circulating blood pDC 
are not activated, yet remain functional during pre-patent blood-stage infection.
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Figure 1. Circulating pDC are not activated in P. falciparum CHMI. (A) Schematic of clinical trial cohorts 
150 pRBC (black) and 1,800 pRBC (grey), arrows indicate antimalarial treatment. (B) Fresh whole blood 
gating strategy for pDC. pDC were identified as negative for lineage markers (CD3, CD14, CD19, CD20, 
CD34 and CD56), HLA-DR+ (2nd panel), CD11c− and CD123+ (3rd panel). (C) Representative flow cytometry 
plots from one participant showing CD86, CD40 and CD80 pDC expression before infection (day 0) and at 
peak-infection. Gated on total DC as shown in Fig. 1B 2nd panel. (D) Longitudinal pDC CD123 and HLA-DR 
expression after 150 pRBC infection. (E) Longitudinal pDC CD123, HLA-DR and HLA-A,B,C expression after 
1,800 pRBC infection. Box plots show the minimum, maximum, median and interquartile range for data from 
all participants (turkey plot). Abbreviations FSC, forward scatter, SSC, side scatter, MFI, median fluorescence 
intensity. 
Figure 2. Characterisation of circulating pDC in clinical patients infected with P. falciparum. (A) The absolute 
number of circulating pDC in 5 healthy controls (black triangles) and 10 patients with acute P. falciparum and at 
convalescence, 14 to 28 days after antimalarial drug treatment (Post Rx). (B) Longitudinal HLA-DR expression 
(MFI) on pDC of patients with acute P. falciparum malaria. (C) Longitudinal CD86 percent positive pDC of 
patients with acute P. falciparum malaria. (D) Longitudinal CD123 expression (MFI) on pDC of patients with 
acute P. falciparum malaria. Mann-Whitney t-test was used for comparison between healthy controls and 
clinical malaria patients. Wilcoxon matched-paired test was used for comparison between acute malaria and 
convalescence (Post Rx). Abbreviations: MFI, median fluorescence intensity.
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While pDC gene expression was largely unchanged during early infection, a panel of eight genes significantly 
increased or decreased at peak-infection. The greatest increase in gene expression was seen in NLRC5 (NOD-like 
receptor (NLR) family, caspase recruitment (CARD) domain containing 5), an IFNγ-inducible transcriptional 
coactivator of MHC class I gene expression also known as CITA (MHC class I transactivator)36. NLRC5 is the 
master regulator of MHC class I gene expression and activates most of the key components of the MHC class I 
antigen presentation pathway37. In line with this, non-classical MHC class I HLA-F was in the top 10 upregulated 
genes in this study, although with a FDR > 0.07. Increased HLA class I protein expression was detected on the 
day after treatment, although not statistically significant. Together these findings suggest that pDC upregulate 
their MHC class I antigen presentation machinery during early P. falciparum infection, whether this leads to 
cross-presentation of parasite antigen to activate CD8+ T cells38 or makes them targets for elimination by cyto-
toxic CD8+ T cells remains unclear. pDC have been suggested to act as a reservoir for Plasmodium in mice39; 
however, we detected no Plasmodium RNA in isolated pDC to support this previous finding, suggesting that this 
does not occur in human pDC or that our methods lacked the sensitivity to identify Plasmodium RNA. Although 
still controversial, NLRC5 has also been reported to modulate type I IFN responses in various human and murine 
cell types40. Future studies into the effects of NLRC5 in malaria are warranted.
Amongst the downregulated genes was BAG3 (BCL2 associated athanogene gene 3), an anti-apoptotic 
co-chaperone protein41. Down-modulation of BAG3 in HIV-infected microglial cells results in accumulation 
Figure 3. Increased pDC active caspase-3 detection. (A) The absolute number of circulating pDC after 1,800 
pRBC infection; arrows indicate day of antimalarial treatment (n = 9 (day 7), n = 24 (day 8)). The absolute 
number of circulating pDC after 150 pRBC infection; arrows indicate day of antimalarial treatment (n = 1 (day 
10), n = 11 (day 11)). Box plots show the minimum, maximum, median and interquartile range for data from all 
participants (turkey plot). Data points outside of box plots represent patients which were outliers. The number 
of individual data points for each day is given below the x-axis. (B) Percentage of pDC positive for active 
caspase-3 after 150 pRBC (n = 6, open circles) or 1,800 pRBC (n = 30, closed circles) infection. The horizontal 
line and whiskers represent the median and inter-quartile range, Wilcoxon matched-paired test was used for 
comparison between day 0 and day 7–8 (peak) or day 10–11 (peak). (C) Mean (+/−SEM) number of circulating 
pDC (white squares) and proportion of active caspase-3 positive pDC (black circles) after 1,800 pRBC infection 
n = 30. Abbreviations: FSC, forward scatter SSC, side scatter, MFI, median fluorescence intensity, SEM, standard 
error of the mean.
www.nature.com/scientificreports/
6Scientific RepoRts | 7: 2596  | DOI:10.1038/s41598-017-02096-2
of active caspase-342. Here we show active caspase-3 detection by flow cytometry in pDC increased in the 1,800 
pRBC cohort during early P. falciparum infection and was associated with pDC loss from the circulation. pDC 
loss equally occurred in the 150 pRBC cohort yet, this did not coincide with active caspase-3 detection. Whether 
this apparent lack of apoptosis in the 150 pRBC cohort is due to differing parasitaemia on the day of treat-
ment or to the longer exposure to a very low parasite dose remains unclear. Very low doses of P. falciparum 
blood-stages have previously been shown to induce host immunity43. The reduction in blood pDC numbers 
during Plasmodium infection is in accordance with previous reports18–23, 27. Additionally, we show for the first 
time, pDC reduce CD123, IL-3α receptor expression in P. falciparum CHMI and in acute falciparum malaria, 
suggesting this effect is independent of the route of infection. Whether this reduction impacts responsiveness to 
IL-3, a T cell derived glycoprotein that supports the viability and differentiation of haematopoietic cells44 remains 
to be determined. Studies of isolated pDC from healthy adults report an increase in pDC CCR7 expression after 
in vitro stimulation with high concentration of P. falciparum schizont antigen18, suggesting pDC increase their 
ability to migrate to lymphoid organs following parasite contact. Whilst we did not detect any changes in CCR7 
gene expression in this early infection, gene expression of CXCR4 was downregulated. pDC constitutively express 
CXCR4 on their surface which is required for their development45 but also allows them to enter lymphoid tissues 
via high endothelial venules46. Downregulation of CXCR4 transcription may indicate less repopulation from the 
bone marrow, reduced ability to migrate to lymphoid tissue or indeed very early activation, as pDC downregu-
late CXCR4 gene expression following in vitro stimulation with Influenza virus47. In the P. yoelii model of severe 
malaria, pDC activation occurs very early during blood-stage infection15, 17 and activated type I IFN producing 
pDC reside predominantly in the bone marrow and blood of P. yoelii YM infected mice15 and not in the spleen 
as previously suggested14, 48. Conclusive evaluation of dendritic cell migration in human malaria will need to be 
addressed by researchers with access to Plasmodium infected human spleen tissue.
Blood pDC are important for maintaining a balance between immunity and immunopathology in viral infec-
tions2. Early production of type I IFNs by pDC are needed for containment of virues in systemic infections such 
as HSV-149. However, pDC derived type I IFNs become less important later on in the infection, as other host cell 
responses become more dominent (reviewed in ref. 2). Moreover, pDC may contribute to the chronicty of HIV 
infection through dysregulated activation and type I IFN production50. The beneficial or detrimental effects of 
pDC and type I IFNs in infection may depend on the timing of their action. In lethal P. yoelii YM infection, early 
Figure 4. pDC cytokine responses to TLR stimulation. (A) Representative staining of circulating pDC in 
PBMC evaluated for intracellular cytokines. pDC were identified as lineage (CD14, CD3, CD19 and CD56)−, 
HLA-DR+, CD11c− and CD123+. Intracellular cytokine production by ex vivo pDC on day 0 (IFN-α and 
TNF) in three conditions: no stimulation (top panel), TLR7 stimulation (middle panel) and TLR9 stimulation 
(bottom panel). (B) IFN-α and TNF produced by pDC on day 0 and day 7 after TLR7 stimulation, n = 8. (C) 
IFN-α and TNF produced by pDC on day 0 and day 7 after TLR9 stimulation, n = 8. (D) IFN-α MFI of IFN-α 
producing pDC after TLR7 or TLR9 stimulation, n = 8. (E) TNF MFI of TNF producing pDC after TLR7 or 
TLR9 stimulation, n = 8. Data are represented as median and interquartile range. The Wilcoxon matched-paired 
test was used for comparison between day 0 and day 7. Abbreviations: FSC, forward scatter SSC, side scatter, 
MFI, median fluorescence intensity.
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 2596  | DOI:10.1038/s41598-017-02096-2
type I IFN production during infection is essential for the induction of protective immune responses17. In con-
trast, type I IFN production in P. berghei ANKA infection, leads to suppression of CD4+ T cell adaptive immune 
responses51, although the cellular sources of IFN-α were not identified. Whether pDC activation is desirable or 
detrimental in human malaria is still not clear.
Assessment of rare human dendritic cell subsets is difficult, and accessing longitudinal human malaria sam-
ples is even more challenging. To gain insights into human pDC function in malaria, we took advantage of the 
CHMI, which allowed longitudinal assessment of pDC function in malaira naive volunteers. Despite loss and 
apparent apoptosis, pDC retained the ability to respond to TLR stimulation. In contrast, during this same time 
frame of early pre-patent P. falciparum infection peripheral blood CD1c+ mDC are dysfunctional and unable to 
upregulate HLA-DR following TLR stimulation28. Together, our studies suggest that DC subsets are differentially 
affected during P. falciparum blood-stage infection and these differences should be considered when evaluating 
dendritic cells in Plasmodium infection and malaria. Evidence of a functional human dendritic cell subset in P. 
falciparum infection is encouraging, as pDC may orchestrate downstream adaptive immune responses during 
infection.
Methods
P. falciparum CHMI. Written and informed consent was obtained from 59 volunteers who participated in 
a series of phase Ib clinical trials testing the efficacy of antimalarial drugs. Blood-stage P. falciparum infection 
was initiated by inoculation of trial parasite doses, 150 (n = 12) or 1,800 (n = 47) parasitised red blood cells 
(pRBC) as previously described29. Anticoagulated blood was collected for immunologic assessment at spe-
cific time points, before and during blood-stage infection. Antimalarial drugs were administered when volun-
teers reached a pre-determined parasitaemia of ≥1,000 parasites/mL (day 10 or 11; 150 pRBC and day 7 or 
8; 1,800 pRBC) (Fig. 1A). Fresh whole blood or cryopreserved peripheral blood mononuclear cells (PBMCs) 
were used in flow cytometric assays. PBMCs were processed within 2 hours of collection. Experimental meth-
ods and studies were approved by Human Research Ethics Committees of QIMR Berghofer Medical Research 
Institute (P1479) and the Human Research Ethics Committees of the NT Department of Health and Menzies 
School of Health Research (HREC 10/1431). All experimental methods were carried out in accordance with 
the NHMRC National Statement on Ethical Conduct of Human Research. Written and informed consent was 
obtained from all participants in the clinical trials. Clinical Trial Registrations; ACTRN12611001203943- reg-
istered 23/11/2011; ACTRN12612000323820- registered 21/03/2012; ACTRN12612000814875- 03/08/2012; 
ACTRN12613000565741-registered 17/05/2013; ACTRN12613001040752- 18/09/2013; NCT02281344- regis-
tered 30/10/2014. Details of the clinical trial protocol and clinical trial registrations are reported elsewhere29, 52.
Acute malaria. The number and phenotype of pDC were assessed in cryopreserved PBMCs collected from 
adults with uncomplicated P. falciparum malaria (n = 10) as part of a pathophysiology study at Queen Elizabeth 1 
and Kudat District Hospitals in Sabah, Malaysia53. PBMC samples were collected prior to commencing treatment, 
Figure 5. Increased HLA-DR, CD123 and CD86 expression on pDC upon TLR stimulation. (A) pDC HLA-DR 
expression (B) pDC CD123 expression and (C) pDC CD86 percent gated on day 0 or day 7, in three conditions: 
no stimulation and after TLR7 or TLR9 stimulation, n = 8. Box plots show the minimum, maximum, median 
and interquartile range for data. Multiple comparisons test (1-way ANOVA) was used for comparison between 
no stimulation and TLR stimulation.
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and again 14 to 28 days in a prospective fashion, after antimalarial drug treatment (Table 2). PBMCs from family 
or friends of patients were evaluated as controls (n = 5). Written informed consent was obtained from partici-
pants and the study was approved by the Human Research Ethics Committees of the NT Department of Health 
and Menzies School of Health Research (HREC 10/1431) and the ethics committee of the Malaysian Ministry 
of Health (NMRR 10 754 6684). All experimental methods were carried out in accordance with the NHMRC 
National Statement on Ethical Conduct of Human Research.
Whole blood pDC and PBMC enumeration and activation. pDC were characterised as lineage (CD3, 
14, 19, 20, 34, 56)−, HLA-DR+, CD11c−, CD123+ (Fig. 1B). In brief, 200 µL of blood or 3 million PBMC were 
stained with surface antibodies; CD3 (HIT3a), CD14 (HCD14), CD19 (HIB19), CD20 (2H7), CD34 (561), 
CD56 (HCD56), HLA-DR (L243), CD11c (B-Ly6), CD123 (6H6), CD86 (2331, FUN-1), CD80 (2D-10), CD40 
(5C3) and HLA-A,B,C (W6/32). All antibodies were purchased from BD Biosciences or Australian Biosearch, 
Biolegend. For whole blood, RBC were lysed with FACS lysing solution (BD, USA) and cells fixed with 1% (w/v) 
paraformaldehyde in phosphate-buffered saline. Absolute numbers of pDC were determined by adding auto-
mated lymphocyte and monocyte counts (109 cells/L), dividing the sum by 100, multiplying the percentage of 
pDC, and multiplying the product by 1,000 to give the cell count/µL.
Apoptosis. Intracellular active caspase-3 was measured as previously described54. Briefly, 200 µL or 1,000 µL 
of blood was stained with surface antibodies, RBC were lysed with FACS lysing solution (BD, USA), cells were 
permeabilised using 1 × BD Perm/Wash™ (BD, USA) and stained with active caspase-3 antibody (C92-605, BD 
USA).
FITC-dextran uptake. pDC phagocytosis was assessed by uptake of 1 mg/mL FITC-dextran (Sigma, USA) 
after 60 min at 37 °C, or on ice as a control, and expressed as delta median fluorescence intensity (ΔMFI) (i.e. 
[MFI of cells at 37 °C]- [MFI control cells on ice]).
Intracellular cytokine staining. Cytokine production was assessed in PBMCs (2 million per well in RPMI 
10% FCS (Invitrogen, USA)) or 1000 µL of WB stimulated with TLR agonists; TLR7: Imiquimod 2.5 µg/mL and 
TLR9: CpG ODN2216 50 ug/mL (Sigma-Aldrich, USA). Protein transport inhibitor (Brefeldin A, BD, USA) was 
added after 2 h at 37 °C, 5% CO2. At 6 h, cells were stained to identify pDC (including CD86 (IT2.2)), washed with 
2% FCS/PBS, cells permeabilised with 1x Perm/Wash™ and stained with intracellular anti-TNF-α (MAB11), 
IL-12/IL-23p40 (C11.5), IL-10 (JES3-9D7), and IFN-α (LT27:295).
FACS data were acquired using a FACSCanto™ II (BD, USA) or Gallios™ (Beckman and Coulter, USA). Data 
were analysed using Kaluza® 1.3 (Beckman Coulter, USA).
pDC isolation and RNA Sequencing. RNA sequencing was performed on paired samples collected prior 
to and at peak-infection from five subjects experimentally infected with 1,800 P. falciparum pRBC. pDC were iso-
lated from fresh PBMCs using the Human Diamond Plasmacytoid Dendritic Cell Isolation Kit (Miltenyi Biotec, 
Gladbach, Germany). In brief, pDC were enriched according to the manufacturer’s instructions using CD304 
(BDCA-4) conjugated microbeads and washed over MACs isolation columns. Purity of isolated pDC cell popu-
lations was checked using flow cytometry (day 0; median 99.3% [IQR 99.1–99.7%], day 7–8 median 99.6% [IQR 
99.3–99.7%]) and the number of isolated pDC was estimated (day 0; median 14,336 cells [IQR 7,487–31,590 
cells], day 7–8 median 38,491 cells [IQR 8,419–66,622 cells]. Isolated pDC were resuspended in RNAprotect 
(Qiagen, Australia) and stored immediately at −80 °C. RNA extraction and RNA-sequencing of five paired par-
ticipant samples were conducted by Macrogen© (Seoul, Korea) using the Illumina TruSeq stranded mRNA LT 
sample kit and the HiSeq 2500 instrument. Transcriptome data were analysed using a modified version of an 
existing variant detection pipeline55 consisting of software STAR aligner56, samtools57, HTSeq58, and DESeq259. 
Reads were first aligned to human reference genome GRCh37 using STAR with the gene model set to gencode 
v19 annotation and quantmode set to TranscriptomeSAM. The alignment files were sorted with samtools and 
the resultant reads input to HTSeq to generate raw read counts using the union overlap resolution mode. Read 
counts were input to DESeq2 and a paired analysis performed for the five participants with baseline and peak 
parasitaemia data.
Healthy Control Acute P. falciparum Post treatment (Rx)
Patients 5 10 10
Age 48 [19–50] 29 [18–45]
Gender (%M) 40% 60%
Parasitaemia . 18,880 [3,077–26,591] .
WCC (103/mL) 7.7 [5.3–10.3] 5.6 [5.0–7.1] 7.9 [6.9–9.4]
Lymphocyte (103/mL) 2.2 [1.7–2.9] 1.2 [0.8–1.5]* 2.3 [1.0–3.3]
Monocyte (103/mL) 0.4 [0.3–0.7] 0.6 [0.5–1.2] 0.6 [0.4–1.0]
Table 2. Acute malaria cohort. Values show the median and [interquartile range]. Comparison between healthy 
controls and acute malaria was performed using a Mann-Whitney t-test, *p ≤ 0.05.
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Statistics. Statistical analyses were undertaken using GraphPad Prism 6 (Graphpad Software Inc., USA). The 
Wilcoxon matched-pairs sign rank test was used to compare longitudinal data and a multiple comparisons test 
(1-way ANOVA) was used for comparison between no stimulation and TLR stimulation.
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